Lexeo Therapeutics

Friedreich ataxia (FA) is a genetic disease that is caused by deficiency in the frataxin protein. Symptoms typically begin in childhood and impact the nervous system (such as impaired muscle coordination, movement issues) and the heart. As the disease progresses, most patients develop heart conditions such as hypertrophic cardiomyopathy and arrhythmias. Although cardiac complications are the leading cause of death in almost 2/3 of patients with FA, there is currently no approved treatment for the heart problems associated with FA. At Lexeo, we are developing LX2006 to address this significant unmet need to address these critical cardiac manifestations: https://lnkd.in/exYWF9U7

We're thrilled to introduce the bright minds joining us this summer!     Our interns play an important role in providing us with fresh perspectives, innovative ideas, and passion for science, all of which are invaluable to our team. Let's give a warm welcome to these future leaders! #OneLexeo 

We are thrilled to share that Jenny Robertson, our Chief Business and Legal Officer, will be participating in a panel discussion at the 11th Annual Summit for Women Leaders in Life Science on Lessons from Women Trailblazers in Life Sciences Law.    Join Jenny for an inspiring session designed to empower women at all career stages. She will share her valuable insights on shattering the glass ceiling, thriving at the executive level, and balancing professional and personal goals.     To learn more about the conference and its speakers, visit: https://lnkd.in/e8KRXTZc     #OneLexeo #WomenInLeadership

During #FAAwarenessMonth, our CEO Nolan Townsend and Jen Farmer, CEO of the Friedreich's Ataxia Research Alliance (FARA), sat down with Karen Jagoda on the Empowered Patient Podcast.     Together, they dove deep into Friedreich ataxia, its cardiac manifestations and clinical research that may provide hope for those living with FA.     Listen to the full episode here: https://lnkd.in/eM_zHqs5

We are proud to share positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across two clinical trials – the SUNRISE-FA Phase 1/2 trial sponsored by Lexeo and a Phase 1A Weill Cornell Medicine investigator-initiated trial – LX2006 was well tolerated with no treatment-related serious adverse events, and clinically meaningful improvements in cardiac biomarkers were observed with increasing improvement over time.   Read more here: https://lnkd.in/e2QD2YKA

Lexeo will present interim clinical data on LX2006, an AAVrh10.hFXN gene therapy candidate for the treatment of Friedreich ataxia (FA) cardiomyopathy, on Monday July 15. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo’s ongoing SUNRISE-FA Phase 1/2 clinical trial and the ongoing Weill Cornell Medicine investigator-initiated trial, as well as an overview of program next steps. https://lnkd.in/e77gXJDN

Happy Independence Day!   We wish everyone a safe, celebratory, and fun holiday to mark our nation’s independence. #OneLexeo

We're excited to feature our VP of clinical development, cardiology, Franca A., MD, PhD in our latest Employee Spotlight! Franca is a key member of our team, bringing passion and dedication to her work in cardiology. Her commitment to innovation and patient care exemplifies the values we hold at Lexeo. Check out the below to learn more about Franca. #OneLexeo 

Arrhythmogenic cardiomyopathy (ACM), a genetic heart disease, is characterized by changes to the heart muscle, which affect its electrical activity. This condition leads to scarring, heart dysfunction and, in severe cases, sudden death. In the US, an estimated 130,000 individuals are affected, and more than half having a genetic cause, primarily associated with mutations in the PKP2 gene.     At Lexeo, we are developing a number of disease-modifying gene therapy candidates to treat cardiovascular diseases with significant unmet need. Our investigational AAV-based gene therapy LX2020, is being evaluated to deliver a fully functional PKP2 gene to heart muscle for the treatment of PKP2-ACM.    Learn more about our AAV-based gene therapy candidate, LX2020:   https://lnkd.in/gNWDX9aQ  

Congratulations to Sarepta Therapeutics on receiving FDA's full approval of their gene therapy for ambulatory Duchenne muscular dystrophy (DMD) in patients four years or older. This is a critical milestone for patients with DMD and their loved ones, and it underscores the importance of accelerated approval as a potential path to get more cell and gene therapies to patients more quickly, especially when unmet needs are high and current treatments do not fully address them. We are excited to see this progress for patients, and within the field, as we work to realize the full potential of genetic medicines.